Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Phensuximide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phensuximide SCHEMBL35333 | 1.00 | KMT2A (1.00) | KMT2ATSHRCYP19A1MEN1MAPT | |
| Methsuximide SCHEMBL28142879 | 0.82 | KMT2A (0.67) | KMT2ATSHRCYP19A1MEN1MAPT | |
| SCHEMBL4974020 | 0.81 | KMT2A (0.69) | KMT2ATSHRCYP19A1MEN1SMN1; SMN2 | |
| SCHEMBL11687430 | 0.81 | KMT2A (0.69) | KMT2ATSHRCYP19A1MEN1SMN1; SMN2 | |
| SCHEMBL9800237 | 0.81 | KMT2A (0.69) | KMT2ATSHRCYP19A1MEN1BRD4 | |
| SCHEMBL8205931 | 0.81 | KMT2A (0.69) | KMT2ATSHRCYP19A1MEN1SMN1; SMN2 | |
| SCHEMBL17583744 | 0.80 | KMT2A (0.66) | KMT2ATSHRCYP19A1MEN1MAPT | |
| Phensuximide SCHEMBL5491858 | 0.80 | KMT2A (0.63) | KMT2ATSHRCYP19A1MEN1MAPT | |
| SCHEMBL29360990 | 0.79 | CYP19A1 (0.71) | KMT2ATSHRCYP19A1MEN1MAPT | |
| SCHEMBL10695532 | 0.79 | TSHR (0.65) | KMT2ATSHRCYP19A1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4942 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4536219-A1 | METHOD OF TREATING EXPRESSIVE LANGUAGE DEFICIT IN AUTISTIC HUMANS | Niesen, Charles, E. (US) | 2025-04-16 | — | — | EP | claimed |
| EP-3518975-B1 | FORMULATION COMPRISING FENFLURAMINE AND CANNABIDIOL AND ITS USE IN THE TREATMENT OF SEIZURES | ZOGENIX INTERNATIONAL LTD (GB) | 2025-04-09 | — | — | EP | claimed |
| US-20240238247-A1 | METHOD OF TREATING EXPRESSIVE LANGUAGE DEFICIT IN AUTISTIC HUMANS | AMS Therapeutics, LLC (US) | 2024-07-18 | — | — | US | claimed |
| WO-2023239964-A1 | METHOD OF TREATING EXPRESSIVE LANGUAGE DEFICIT IN AUTISTIC HUMANS | NIESEN CHARLES E (US) | 2023-12-14 | — | — | WO | claimed |
| US-11786487-B2 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | ZOGENIX INTERNATIONAL LIMITED (GB) | 2023-10-17 | — | — | US | claimed |
| WO-2023178250-A1 | TREATMENT OF TUBEROUS SCLEROSIS WITH MIRDAMETINIB | SpringWorks Therapeutics Inc. (US) | 2023-09-21 | — | — | WO | claimed |
| US-11759440-B2 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | ZOGENIX INTERNATIONAL LIMITED (GB) | 2023-09-19 | — | — | US | claimed |
| EP-4232004-A1 | FRACTAL FORMULATIONS | Nanogyre Sprl (BE) | 2023-08-30 | — | — | EP | claimed |
| US-20230218623-A1 | SALTS OF NEUROCEUTICALS AND USES THEREOF | SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) | 2023-07-13 | — | — | US | claimed |
| CN-115836074-A | Salts of neurological drugs and uses thereof | 心悦生医股份有限公司 | 2023-03-21 | — | — | CN | claimed |
| EP-0942752-A1 | ANTICONVULSANT CONTAINING COMPOSITION FOR TREATING NEUROPATHIC PAIN | Algos Pharmaceutical Corporation (US) | 1999-09-22 | — | — | EP | claimed |
| US-5955103-A | Dosage form comprising antiepileptic drug | ALZA CORPORATION (US) | 1999-09-21 | — | — | US | claimed |
| US-5906832-A | Method for treating epilepsies | ALZA CORPORATION (US) | 1999-05-25 | — | — | US | claimed |
| US-5876750-A | Effective therapy for epilepsies | ALZA CORPORATION (US) | 1999-03-02 | — | — | US | claimed |
| US-5863558-A | Effective therapy for epilepsies | ALZA CORPORATION (US) | 1999-01-26 | — | — | US | claimed |
| WO-1998007447-A1 | ANTICONVULSANT CONTAINING COMPOSITION FOR TREATING NEUROPATHIC PAIN | ALGOS PHARMACEUTICAL CORPORATION (US) | 1998-02-26 | — | — | WO | claimed |
| EP-0758228-A1 | EFFECTIVE DOSAGE FORM FOR ANTIEPILEPTIC DRUGS | ALZA CORPORATION (US) | 1997-02-19 | — | — | EP | claimed |
| WO-1995029665-A1 | EFFECTIVE DOSAGE FORM FOR ANTIEPILEPTIC DRUGS | ALZA CORPORATION (US) | 1995-11-09 | — | — | WO | claimed |
| US-5192550-A | Dosage form for treating central nervous system disorders | ALZA CORPORATION (US) | 1993-03-09 | — | — | US | claimed |
| US-4160818-A | Fluorimetric immunoassay for diphenylhydantoin | TECHNICON INSTRUMENTS CORPORATION (US) | 1979-07-10 | — | — | US | claimed |